News and Announcements
Analytica Limited (ASX: ALT) completes Renouncable Entitlement Offer with over $1 million raised
- Published June 08, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Analytica Limited has announced the successful completion of the renounceable entitlement offer with $1.045m raised.
- The Entitlement offered one new share for every eight shares held on the 21 of September 2017.
- The entitlement offer aimed to raise funds to continue the development of their PeriCoach system.
Analytica Limited has announced the successful completion of their entitlement offer that was announced in September 2017. The renounceable entitlement offer resulted in $1.045m raised through options exercised before the expiration of two options provided. The Entitlement offered one new share for every eight shares held on the 21 of September 2017. Option 1 stated that shares subscribed to are exercisable at $0.005 on or before 31 January 2018, or Option 2 exercisable at $0.005 on or before 31 May 2018. Following Option 1, a total of $919k worth of exercised options was raised and Option 2 raised a total of $1.045k through the exercised options. A further $487k was raised from private placements with unlisted options exercisable at the same $0.005.
The entitlement offer aimed to raise funds to continue the development of their PeriCoach system. PeriCoach is a medical system that allows remote physicians to monitor a woman’s Stress Urinary Incontinence condition. The support of shareholders in pursuing this goal of development was appreciated by Analytica Limited, and the shares will be allocated on 13 June 2018.
About Analytica Limited (ASX: ALT)
Analytica Limited (ASX: ALT) is an Australian medical device manufacturing and commercialisation company.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
